Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
Open Access
- 15 December 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 2 (12), e243
- https://doi.org/10.1038/cddis.2011.129
Abstract
Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma) were continuously exposed to increasing concentrations of the murine double minute 2 inhibitor nutlin-3, resulting in the emergence of nutlin-3-resistant, p53-mutated sublines displaying a multi-drug resistance phenotype. Only 2 out of 28 sublines adapted to various cytotoxic drugs harboured p53 mutations. Nutlin-3-adapted UKF-NB-3 cells (UKF-NB-3rNutlin10 μM, harbouring a G245C mutation) were also radiation resistant. Analysis of UKF-NB-3 and UKF-NB-3rNutlin10 μM cells by RNA interference experiments and lentiviral transduction of wild-type p53 into p53-mutated UKF-NB-3rNutlin10 μM cells revealed that the loss of p53 function contributes to the multi-drug resistance of UKF-NB-3rNutlin10 μM cells. Bioinformatics PANTHER pathway analysis based on microarray measurements of mRNA abundance indicated a substantial overlap in the signalling pathways differentially regulated between UKF-NB-3rNutlin10 μM and UKF-NB-3 and between UKF-NB-3 and its cisplatin-, doxorubicin-, or vincristine-resistant sublines. Repeated nutlin-3 adaptation of neuroblastoma cells resulted in sublines harbouring various p53 mutations with high frequency. A p53 wild-type single cell-derived UKF-NB-3 clone was adapted to nutlin-3 in independent experiments. Eight out of ten resulting sublines were p53-mutated harbouring six different p53 mutations. This indicates that nutlin-3 induces de novo p53 mutations not initially present in the original cell population. Therefore, nutlin-3-treated cancer patients should be carefully monitored for the emergence of p53-mutated, multi-drug-resistant cells.Keywords
This publication has 40 references indexed in Scilit:
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic ProfilingJournal of Clinical Oncology, 2011
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3Oncogene, 2011
- A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiationBMC Cancer, 2011
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaClinical Cancer Research, 2010
- DNA damage response to the Mdm2 inhibitor Nutlin-3Biochemical Pharmacology, 2010
- MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53British Journal of Cancer, 2009
- Transient Nutlin-3a Treatment Promotes Endoreduplication and the Generation of Therapy-Resistant Tetraploid CellsCancer Research, 2008
- Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic PropertiesPLOS ONE, 2008
- PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathwaysNucleic Acids Research, 2006
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004